Natixis Advisors L.P. Sells 25,989 Shares of Core Laboratories (NYSE:CLB)

Natixis Advisors L.P. lowered its stake in Core Laboratories (NYSE:CLB) by 23.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 83,333 shares of the oil and gas company’s stock after selling 25,989 shares during the quarter. Natixis Advisors L.P. owned about 0.19% of Core Laboratories worth $4,357,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Marshall Wace LLP acquired a new stake in shares of Core Laboratories in the 1st quarter valued at about $30,000. Bremer Bank National Association bought a new stake in shares of Core Laboratories during the first quarter worth approximately $30,000. NEXT Financial Group Inc acquired a new stake in shares of Core Laboratories in the second quarter valued at approximately $31,000. Advisory Services Network LLC raised its position in shares of Core Laboratories by 306.5% in the second quarter. Advisory Services Network LLC now owns 1,809 shares of the oil and gas company’s stock valued at $95,000 after buying an additional 1,364 shares in the last quarter. Finally, First Bank & Trust raised its position in shares of Core Laboratories by 20.8% in the second quarter. First Bank & Trust now owns 2,852 shares of the oil and gas company’s stock valued at $149,000 after buying an additional 492 shares in the last quarter.

Shares of NYSE CLB traded down $0.33 during midday trading on Friday, reaching $46.65. 22,701 shares of the company were exchanged, compared to its average volume of 547,835. The stock’s 50-day moving average price is $42.59 and its 200-day moving average price is $55.66. The stock has a market cap of $2.02 billion, a P/E ratio of 20.48, a PEG ratio of 4.86 and a beta of 1.95. Core Laboratories has a one year low of $36.61 and a one year high of $122.11. The company has a quick ratio of 1.41, a current ratio of 1.80 and a debt-to-equity ratio of 1.83.

Core Laboratories (NYSE:CLB) last posted its earnings results on Wednesday, July 24th. The oil and gas company reported $0.46 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.46. The firm had revenue of $169.04 million for the quarter, compared to analysts’ expectations of $173.46 million. Core Laboratories had a net margin of 14.30% and a return on equity of 51.19%. The company’s revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 earnings per share. On average, equities research analysts anticipate that Core Laboratories will post 1.75 EPS for the current year.

In related news, Director Gregory Barry Barnett bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 13th. The shares were purchased at an average price of $40.00 per share, with a total value of $40,000.00. Following the completion of the purchase, the director now owns 11,000 shares in the company, valued at approximately $440,000. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 2.00% of the company’s stock.

A number of research firms have recently weighed in on CLB. Bank of America upgraded shares of Core Laboratories from a “neutral” rating to a “buy” rating and set a $63.00 price target for the company in a research report on Wednesday, July 10th. Royal Bank of Canada set a $77.00 price target on shares of Core Laboratories and gave the company a “buy” rating in a research report on Wednesday, June 26th. Piper Jaffray Companies set a $52.00 price target on shares of Core Laboratories and gave the company a “hold” rating in a research report on Wednesday, June 26th. Morgan Stanley dropped their price target on shares of Core Laboratories from $75.00 to $70.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th. Finally, ValuEngine downgraded shares of Core Laboratories from a “sell” rating to a “strong sell” rating in a research report on Monday, July 29th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $74.42.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit